A sharp increase in the demand for immunoglobulins has been recorded in Italy over the past ten years, making it more difficult to achieve self-sufficiency in plasma-derived medicinal products, despite the significant progress made in plasma collection in recent years. These are just some of the figures presented during the event entitled “Plasma-Derived Medicines in Italy – Results and Challenges of a Value-Based System”, organised by the National Blood Centre and held in Bologna in recent days.

During the meeting, it emerged that from 2014 to 2024 the demand for polyvalent immunoglobulins (the main driver of plasma-derived product manufacturing, together with albumin) increased by 57%, with an average annual growth rate of around 5%. This rise is mainly driven by the greater use of subcutaneous immunoglobulins, whose consumption has grown from 8 grams per 1,000 inhabitants to about 28 grams over ten years (+245%). The use of intravenous immunoglobulins has also increased, rising from approximately 65 to 87 grams per 1,000 inhabitants (+34%).

Positive results, however, emerge from the analysis of plasma collection data over the past two years, which show two consecutive record highs, surpassing the threshold of 900 tonnes collected in 2024. There has also been a 9% increase over ten years in plasmapheresis procedures — those that, through the use of a cell separator, allow donors to give only plasma, the liquid component of blood, while red blood cells and platelets are reinfused to the donor.

The data on self-sufficiency, however, do not follow the same trend, particularly with regard to the overall demand for immunoglobulins. While the level of self-sufficiency for albumin recorded in 2024 stands at 76% of total demand, for immunoglobulins the figure is 59% — slightly lower than ten years ago, when, also due to significantly lower usage, it stood at 62%. This means that only 59% of the total demand for polyvalent immunoglobulins used by Italian patients is met through plasma donated in Italy, while the remaining 41% must be covered by purchasing medicines on the international market.

“Meetings such as the one held in Bologna,” commented Luciana Teofili, Director of the National Blood Centre, “allow us to highlight the importance of a vital resource for the National Health Service — plasma. It is thanks to plasma that plasma-derived medicines are produced, which are also used in numerous life-saving therapies. However, the figures concerning immunoglobulins point to the need for a necessary reflection on the appropriateness of the clinical use of these strategic medicines — a reflection that is already under way with AIFA (Italian Medicines Agency), but which should be extended to sector professionals both at the local and international level.”

Plasmapheresis
It is a dedicated collection carried out using a device (cell separator) which immediately separates the corpuscular part, i.e. red and white blood cells and platelets, from the liquid component which is collected in a bag of approximately 600-700 ml. The corpuscular part is reinfused into the donor. The volume of liquid that is removed with the donation is reconstituted thanks to natural recovery mechanisms, the infusion of physiological solution and the intake of liquids.


The Production of Medicines from National Plasma
Plasma is supplied to the pharmaceutical industry, where it is used to produce life-saving medicines known as plasma-derived products, such as immunoglobulins, albumin, and coagulation factors. The medicines produced from donated plasma are not used for commercial purposes; once processing is complete, they are returned to the healthcare facilities of Italy’s Regions and Autonomous Provinces. Plasma-derived medicines are distributed free of charge to patients who need them, and any batches exceeding national requirements are donated to countries in need through international cooperation programmes.


For info:
www.italiaplasma.it